dCK Antibody (H-5): sc-393098

dCK Antibody (H-5) is a mouse monoclonal IgG2b antibody that detects dCK in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). dCK, or deoxycytidine kinase, plays a crucial role in nucleotide metabolism by catalyzing the phosphorylation of deoxyribonucleosides, which is essential for DNA synthesis and repair. This enzymatic activity is particularly important in cellular proliferation and response to DNA damage, as anti-dCK antibody (H-5) helps detect dCK involvement in the activation of several antiviral and chemotherapeutic nucleoside analogs. Notably, dCK expression is linked to drug sensitivity; deficiencies in dCK activity can lead to resistance against these therapeutic agents, making dCK a significant target for cancer and viral infection treatments. dCK (H-5) antibody detects the protein predominantly in the cytosol, where dCK interacts with other metabolic enzymes and substrates, highlighting its integral role in maintaining nucleotide pools necessary for DNA replication and repair. dCK monoclonal antibody (H-5) serves as an invaluable tool for researchers studying nucleotide metabolism, drug resistance mechanisms, and the therapeutic potential of nucleoside analogs.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

dCK Antibody (H-5) References:

1. Casein kinase 1delta activates human recombinant deoxycytidine kinase by Ser-74 phosphorylation, but is not involved in the in vivo regulation of its activity.  |  Smal, C., et al. 2010. Arch Biochem Biophys. 502: 44-52. PMID: 20637175
2. Deoxycytidine kinase, thymidine kinase and cytidine deaminase and the formation of Ara-CTP in leukemic cells in different phases of the cell cycle.  |  Richel, DJ., et al. 1990. Leuk Res. 14: 363-9. PMID: 2159090
3. Development of new deoxycytidine kinase inhibitors and noninvasive in vivo evaluation using positron emission tomography.  |  Murphy, JM., et al. 2013. J Med Chem. 56: 6696-708. PMID: 23947754
4. Deoxycytidine kinase promotes the migration and invasion of fibroblast-like synoviocytes from rheumatoid arthritis patients.  |  Fan, W., et al. 2013. Int J Clin Exp Pathol. 6: 2733-44. PMID: 24294360
5. Structure-guided development of deoxycytidine kinase inhibitors with nanomolar affinity and improved metabolic stability.  |  Nomme, J., et al. 2014. J Med Chem. 57: 9480-94. PMID: 25341194
6. Human deoxycytidine kinase. Sequence of cDNA clones and analysis of expression in cell lines with and without enzyme activity.  |  Huang, SH., et al. 1989. J Biol Chem. 264: 14762-8. PMID: 2549034
7. Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase.  |  Vena, F., et al. 2020. Mol Cancer Ther. 19: 1623-1635. PMID: 32430484
8. Different Susceptibility of T and B Cells to Cladribine Depends On Their Levels of Deoxycytidine Kinase Activity Linked to Activation Status.  |  Carlini, F., et al. 2022. J Neuroimmune Pharmacol. 17: 195-205. PMID: 33851318
9. Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms.  |  Yoshida, K., et al. 2022. Cancer Chemother Pharmacol. 89: 83-91. PMID: 34825941
10. Deoxycytidine kinase and thymidine kinase activities in rat brain.  |  Singhal, RL. and Weber, G. 1993. Oncol Res. 5: 191-5. PMID: 8305745

The preferred dCK antibody is dCK Antibody (H-3): sc-393099.